FREQUENTLY ASKED
Questions
What is transcranial direct current stimulation (tDCS)?
Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique that delivers a weak, constant electrical current — typically 1 to 2 milliamps — to the scalp through electrodes. Rather than triggering neurons to fire directly, tDCS shifts their resting membrane potential, making them more or less excitable in response to incoming signals. Effects are strongest when stimulation coincides with active cognitive engagement in the target brain region.
Is tDCS safe to use at home?
Based on the most comprehensive safety review in the field (Bikson et al., 2016, PMID 27372845), which analyzed over 33,200 sessions across more than 1,000 subjects including children, the elderly, and people with epilepsy or mood disorders, no serious adverse effects or irreversible injuries were reported at conventional parameters (≤40 minutes, ≤4 mA). Mild scalp tingling is the most commonly reported sensation. Sychedelic operates at 2 mA, well within this established safety range.
Why does Sychedelic target the dorsolateral prefrontal cortex (DLPFC)?
The DLPFC is the brain region most directly responsible for working memory, executive function, sustained attention, and impulse control — neurologically what "focus" means. Reduced DLPFC activity is linked to ADHD, depression, age-related cognitive decline, and stress-induced performance impairment. Anodal tDCS applied to the DLPFC at electrode sites F3 and F4 is one of the most studied stimulation protocols in cognitive neuroscience.
How is Sychedelic different from a stress wearable like Oura or Whoop?
Stress wearables read physiological signals and report them back to you. Sychedelic reads the same signals — PPG-derived HRV — and uses them as inputs to a decision system that determines whether and when to activate tDCS stimulation and adaptive audio. The output is an intervention, not a score. Most wellness wearables close two stages of the loop (measure and report); Sychedelic closes all three (measure, interpret, and intervene).
How many tDCS sessions are needed before seeing results?
Single-session effects in healthy, well-rested adults are inconsistent across studies. Evidence is substantially stronger for multi-session protocols, typically 10 to 20 sessions, which may produce neuroplastic changes that extend beyond each session. Sychedelic's protocol — Calibration (sessions 1–5), First Signal (6–15), Consolidation (16–25), Maintenance (26+) — is structured around this finding. Effects are most reliable when stimulation occurs concurrently with active cognitive work.
Is tDCS better than neurofeedback for improving focus?
For consumer use outside clinical settings, tDCS has practical advantages: it doesn't rely on EEG signal quality, requires no active user training, and effects begin within sessions rather than accumulating over months of behavioral conditioning. For clinical populations with research-grade EEG equipment and trained practitioners, neurofeedback has its own well-documented evidence base. The comparison is context-dependent, not absolute.
Why doesn't Sychedelic use red-light therapy instead of tDCS?
Red-light therapy (photobiomodulation) and tDCS operate through entirely different mechanisms. The photobiomodulation evidence base is still developing — optimal wavelength, dosing, and skull penetration depth remain active areas of investigation. tDCS has over two decades of peer-reviewed research, established dosing parameters, a defined safety profile across 33,200+ sessions (Bikson et al., 2016), and a direct mechanistic pathway to the DLPFC networks governing executive function.
What is closed-loop neuromodulation and how does it work in Sychedelic?
A closed-loop neuromodulation system continuously reads a physiological signal — in Sychedelic's case, heart rate variability via PPG — and uses that reading to determine whether stimulation is activated, rather than running on a fixed preset schedule. tDCS only activates once HRV confirms your nervous system has reached a readiness threshold. This matters because tDCS effects are state-dependent: stimulating an aroused or dysregulated nervous system produces different outcomes than stimulating a calm, prepared one.
Does everyone respond to tDCS the same way?
No. Research consistently shows that approximately 30–40% of individuals appear to be non-responders to tDCS in controlled settings. This likely reflects differences in individual neuroanatomy, skull thickness, baseline neural state, and electrode placement accuracy. The protocol that works well for the majority may not produce the same effects for everyone — an honest limitation that Sychedelic's own science documentation acknowledges.
What should I realistically expect from tDCS?
The evidence supports small-to-moderate effect sizes in healthy adult populations. tDCS is not a cognitive amplifier in any dramatic sense; it produces incremental shifts in cortical excitability that appear to support performance, particularly under conditions of stress or fatigue. Users who perform cognitive work during the post-stimulation window (approximately 90 minutes after stimulation ends) appear to benefit most. Expect consistent, meaningful support for focused work, not a shortcut to peak performance.
Is Sychedelic a medical device?
Sychedelic holds CDSCO approval (the Indian regulatory body's clearance for medical devices, equivalent in function to FDA clearance) and IEC 60601-1-2 certification. The well-characterized safety parameters of tDCS at 1–2 mA, documented across 33,200+ sessions in the peer-reviewed literature, supported a regulatory pathway clearer than less-studied modalities would have allowed.
Can tDCS help with sleep in addition to focus?
There is growing multi-session evidence for sleep-related outcomes. Zhou et al. (2020, PMID 32179428) conducted a 90-participant, double-blind RCT with a 20-session DLPFC tDCS protocol and found significant improvements in sleep quality and sleep onset latency, sustained through a maintenance phase. Whether Sychedelic's specific implementation produces comparable sleep outcomes requires device-specific evidence beyond what the general tDCS literature established.